Editas Medicine, Inc. (EDIT) — Financial statements
Income statement, balance sheet, and cash flow for Editas Medicine, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 41↑25.4% | 32↓58.6% | 78↑296.3% | 20↓22.8% | 26 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 6↓4.3% | 6↑25.4% | 5 | |
| Gross Profit | 41↑25.4% | 32↓55.2% | 72↑438.8% | 13↓34.7% | 20 | |
| Operating Expenses | ||||||
| R&D Expenses | 90↓54.9% | 199↑12.2% | 178↑1.5% | 175↑22.8% | 143 | |
| General & Administrative Expenses | 50↓30.7% | 72↑3.4% | 70↓1.5% | 71↓7.2% | 76 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 50↓30.7% | 72↑3.4% | 70↓1.5% | 71↓7.2% | 76 | |
| Other Expenses | 0.00↓100.0% | 12↑301.7% | -6↑4.3% | -6↓25.4% | -5 | |
| Operating Expenses | 140↓50.7% | 283↑17.5% | 241↑0.8% | 239↑12.0% | 214 | |
| Total Costs & Expenses | 140↓50.7% | 283↑14.6% | 247↑0.7% | 246↑12.3% | 219 | |
| Operating Results | ||||||
| Operating Income | -99↑60.4% | -251↓48.5% | -169↑25.1% | -226↓17.0% | -193 | |
| Depreciation & Amortization | 5↓9.2% | 6↓4.2% | 6↓4.3% | 6↑25.4% | 5 | |
| EBITDA | -149↑36.2% | -233↓42.9% | -163↑25.7% | -220↓16.8% | -188 | |
| EBIT | -154↑35.6% | -239↓41.2% | -169↑25.1% | -226↓17.0% | -193 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓84.8% | 14↓19.9% | 18↑218.3% | 6↑809.1% | 0.61 | |
| Interest Income | 8↓40.9% | 14↓19.9% | 18↑218.3% | 6↑809.1% | 0.61 | |
| Interest Expense | 6 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 55↑546.0% | -12 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -61↓531.9% | 14↓11.9% | 16↑189.3% | 6↑756.8% | 0.64 | |
| Income Before Tax | -160↑32.5% | -237↓54.7% | -153↑30.5% | -220↓14.5% | -193 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -160↑32.5% | -237↓54.7% | -153↑30.5% | -220↓14.5% | -193 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -160↑32.5% | -237↓54.7% | -153↑30.5% | -220↓14.5% | -193 | |
| Bottom-Line Net Income | -160↑32.5% | -237↓54.7% | -153↑30.5% | -220↓14.5% | -193 | |
| EPS (Basic) | -1.80↑37.5% | -2.88↓42.6% | -2.02↑37.1% | -3.21↓12.6% | -2.85 | |
| EPS (Diluted) | -1.80↑37.5% | -2.88↓42.6% | -2.02↑37.1% | -3.21↓12.6% | -2.85 | |
| Weighted Average Shares | 89↑7.8% | 82↑8.4% | 76↑10.6% | 69↑1.5% | 68 | |
| Weighted Average Diluted Shares | 89↑7.8% | 82↑8.4% | 76↑10.6% | 69↑1.5% | 68 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.